Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 21, 2019 07:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Expands Commercial Management Team Ahead of Planned Talicia® Launch

Rob Jackson joins as Vice President of MarketingRobert J. Gilkin, Jr. joins as Vice President of Market AccessSteven Thomasian to join as Vice President of Supply Chain TEL-AVIV, Israel and RALEIGH,...
October 24, 2018 08:00 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Final Patient Assessed in Confirmatory Phase III Study with TALICIA® for H. pylori Infection

RedHill will host an Analyst and Investor Webcast on TALICIA® for H. pylori infection on Tuesday, October 30, 2018, at 8:30 a.m. EDTFinal patient assessed for primary endpoint, with top-line results...
March 02, 2015 07:00 ET | Source: RedHill Biopharma Ltd.

Positive Bioavailability Studies of RedHill's BEKINDA(TM) to be Presented at the 2015 American Society for Clinical Pharmacology and Therapeutics (ASCPT) Meeting

The results from two positive bioavailability studies, previously reported by the Company, demonstrate the safety and tolerability of BEKINDA™ and support the European marketing application...
February 18, 2015 09:56 ET | Source: RedHill Biopharma Ltd.

RedHill Biopharma Announces Full Exercise of Underwriters' Over-Allotment Option

TEL-AVIV, Israel, Feb. 18, 2015 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill" or the "Company"), an Israeli biopharmaceutical company primarily focused on late...
November 08, 2011 16:42 ET | Source: Pressure BioSciences, Inc.

Pressure BioSciences, Inc. to Discuss Third Quarter 2011 Financial Results and Provide Business Update

SOUTH EASTON, Mass., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Pressure BioSciences, Inc. (Nasdaq:PBIO) ("PBI" and the "Company") today announced that the Company will host a teleconference to discuss its...